Design, construction, and in vitro analyses of multivalent antibodies

Journal of Immunology

Volumn 170, Issue 9, 2003, Pages 4854-4861

  Miller, Kathy ^a,b   Meng, Gloria ^a   Liu, Jun ^a   Hurst, Amy ^a   Hsei, Vanessa ^a   Wong, Wai Lee ^a   Ekert, Rene ^a   Lawrence, David ^a   Sherwood, Steven ^a   DeForge, Laura ^a   Gaudreault, Jacques ^a   Keller, Gilbert ^a   Sliwkowski, Mark ^a   Ashkenazi, Avi ^a   Presta, Leonard ^a  

^a GENENTECH INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CELL SURFACE RECEPTOR; DEATH RECEPTOR 5; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; POLYMER; UNCLASSIFIED DRUG;

ARTICLE; CELL SURFACE; CROSS LINKING; GENE AMPLIFICATION; GENE CONSTRUCT; HUMAN; HUMAN CELL; IN VITRO STUDY; ONCOGENE NEU; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0242500331     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.9.4854     Document Type: Article

References (63)

1. Carter, P., L. Presta, C. M. Gorman, J. B. B. Ridgway, D. Henner, W. L. T. Wong, A. M. Rowland, C. Kotts, M. E. Carver, and M. H. Shepard. 1992. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89:4285.
2. Leget, G. A., and M. S. Czuczman. 1998. Use of Rituximab, the new FDAapproved antibody. Curr. Opin. Oncol. 10:548.
3. Sievers, E. L., F. R. Appelbaum, R. T. Spielberger, S. J. Forman, D. Flowers, F. O. Smith, K. Shannon-Dorcy, M. S. Berger, and I. D. Bernstein. 1999. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93:3678.
4. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6:443.
5. Ghetie, M., E. M. Podar, A. Ilgen, B. E. Gordon, J. W. Uhr, and E. S. Vitetta. 1997. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc. Natl. Acad. Sci. USA 94:75.
6. Ghetie, M.-A., H. Bright, and E. S. Vitetta. 2001. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 97: 1392.
7. Zhao, Y., and H. Kohler. 2002. Enhancing tumor targeting and apoptosis using noncovalent antibody homodimers. J. Immunother. 25:396.
8. Klemm, J. D., S. L. Schreiber, and G. R. Crabtree. 1998. Dimerization as a regulatory mechanism in signal transduction. Annu. Rev. Immunol. 16:569.
9. Di Fiiore, P. P., and G. N. Gill. 1999. Endocytosis and mitogenic signaling. Curr. Opin. Cell Biol. 11:483.
10. 3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells. J. Immunol, 17:60.
11. Kan, K. S., V. A. Anderson, W. S. Leong, A. M. Smith, A. T. Worth, and G. T. Stevenson. 2001. Thioether-bonded constructs of Fab′γ and Fc′γ modules utilizing differential reduction of interchain disulfide bonds. J. Immunol. 166: 1320.
12. Dickler, H. B., and M. T. Kubicek. 1988. Effects of various forms of monoclonal anti-FcγRII (2.4G2) on B lymphocyte responses. Mol. Immunol. 25:1169.
13. Olafsen, T., I. B. Rasmussen, L. Norderhaug, O. S. Bruland, I. Sandlie. 1998. IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells. Immunotechnology 4:141.
14. Choi, I., W. E. Schmitt, A. Bahre, M. Little, and B. Cochlovius. 2002. Recombinant chimeric OKT3/IgM antibodies for immune suppression: evaluation in a human CD3 transgenic mouse model. Immunol. Lett. 80:125.
15. Smith, R. I. F., M. J. Coloma, and S. L. Morrison. 1995. Addition of a μ-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4. J. Immunol. 154:2226.
16. Coloma, M. J., and S. L. Morrison. 1997. Design and production of novel tetravalent bispecific antibodies. Nat. Biotechnol. 15:159.
17. Pluckthun, A., and P. Pack. 1997. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 3:83.
18. Todorovska, A., R. C. Roovers, O. Dolezsal, A. A. Kortt, H. R. Hoogenboom, and P. J. Hudson. 2001. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods 248:47.
19. Hu, S.-Z., L. Shively, A. Raubitschek, M. Sherman, L. E. Williams, J. Y. C. Wong, J. E. Shively, and A. M. Wu. 1996. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56:3055.
20. Alt, M., R. Miller, and R. E. Kontermann. 1999. Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin γ1 Fc or CH3 region. FEBS Lett. 454:90.
21. Worn, A., and A. Pluckthun. 2001. Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. 305:989.
22. HER-2 miniantibodies multimerized by self-associating peptides. J. Biol. Chem. 276:14385.
23. 2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity. Protein Eng. 8:1057.
24. Slamon, D., G. Clark, S. Wong, W. Levin, A. Ullrich, and W. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177.
25. Colomer, R., L. A. Shamon, M. S. Tsai, and R. Lupu. 2001. Herceptin: from the bench to the clinic. Cancer Invest. 19:49.
26. Riley, J. K., and M. X. Sliwkowski. 2000. CD20: a gene in search of a function. Semin. Oncol. 27:17.
27. Ashkenazi, A., and Dixit, V. M. 1998. Death receptors: signaling and modulation. Science 281:1305.
28. Kabat, E. A., T. T. Wu, H. M. Perry, K. S. Gottesman, and C. Foeller. 1991. Sequences of Proteins of Immunological Interest. U.S. Department of Health and Human Services, Natl. Inst. of Health, Bethesda.
29. Eaton, D. L., W. I. Wood, D. Eaton, P. E. Hass, P. Hollingshead, K. Wion, J. Mather, R. M. Lawn, G. A. Vehar, and C. Gorman. 1986. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry 25:8343.
30. Kunkel, T. A. 1985. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc. Natl. Acad. Sci. USA 82:448.
31. Gorman, C. M., D. R. Gies, and G. McCray. 1990. Transient production of proteins using an adenovirus transformed cell line. DNA Protein Eng. Techniq. 2:3.
32. 2L/TRAIL/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12:611.
33. Karlsson, R., H. Roos, L. Fagerstam, and B. Persson. 1994. Kinetic and concentration analysis using BIA technology. Methods 6:97.
34. Morton, T. A., and D. G. Myszka. 1998. Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. Methods Enzymol. 295: 268.
35. Shire, S. J., and J. Liu. 1999. Analytical ultracentrifugation in the pharmaceutical industry. J. Pharm. Sci. 88:1237.
36. HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37:255.
37. Ashkenazi, A., R. C. Pai, S. Fong, S. Leung, D. A. Lawrence, S. A. Marsters, C. Blackie, L. Chang, A. E. McMurtrey, A. Hebert, et al. 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104:155.
38. Koopman, G., C. P. Reutelingsperger, G. A. Kluijten, R. M. Keehnen, S. T. Pals, and M. H. van Oers. 1994. Annexin V for flow cytometric detection of phosphatidylserine expression on cells undergoing apoptosis. Blood 84:1415.
39. Kerr, J. F. R., A. H. Wylie, and A. R. Curie. 1972. Apoptosis: a basic biological phenomenon with wide-ranging implications for tissue kinetics. Br. J. Cancer 26:239.
40. Li, W., J. W. Park, A. Nuijens, M. X. Sliwkowski, and G.-A. Keller. 1996. Heregulin is rapidly translocated to the nucleus and its transport is correlated with c-myc induction in breast cancer cells. Oncogene 12:2473,
41. HER2 in biological fluids. J. Immunol. Methods 132:7.
42. 2 by aminespecific PEGylation with preserved bioactivity. Int. J. Pharm. 198:3.
43. Yamamoto, T., S. Ikawa, T. Akiyama, K. Semba, N. Nomura, N. Miyajima, T. Saito, and K. Toyoshima. 1986. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319:230.
44. Ashkenazi, A., and V. M. Dixit. 1999. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11:255.
45. Stennicke, H. R., and G. S. Salvesen. 1999. Caspases: preparation and characterization. Methods 17:313.
46. Greyer, M. R., S. A. Schepartz, and B. A. Chabner. 1992. The National Cancer Institute: cancer drug discovery and development program. Semin. Oncol. 19: 622.
47. 2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl. Acad. Sci. USA 93:5512.
48. Telleman, P., and R. P. Junghans. 2000. The role of the Brambel receptor (FcRB) in liver: protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than the transport of IgG to bile. Immunology 100:245.
49. Caron, P. C., W. Laird, M. S. Co, M. M. Avdalovic, C. Queen, and D. A. Sheinberg. 1992. Engineered humanized dimeric forms of IgG are more effective antibodies. J. Exp. Med. 176:1191.
50. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9:1165.
51. Sliwkowski, M. X., J. A, Lofgren, G. D. Lewis, T. E. Hotaling, B. M. Fendly, and J. A. Fox. 1999. Nonclinical studies addressing the mechanism of action of Trastuzumab (Herceptin). Semin. Oncol. 26:60.
52. Anderson, D. R., A. Grillo-Lopez, C. Varns, K. S. Chambers, and N. Hanna. 1997. Targeted anti-cancer therapy using Rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8), in the treatment of non-Hodgkin's B-cell lymphoma: Biochem. Soc. Trans. 25:705.
53. Cartron, G., L. Dacheux, G. Salles,P. Solal-Celigny, P. Bardos, P, Colombat and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99:754.
54. Hudson, P. J. 1999. Recombinant antibody constructs in cancer therapy. Curr. Opin. Immunol. 11:548.
55. Nielsen, U. B., G. P. Adams, L. M. Weiner, and J. D. Marks. 2000. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res. 60:6434.
56. Adams, G. P., R. Schier, A. M. McCall, H. H. Simmons, E. M. Horak, R. K. Alpaugh, J. D. Marks, and L. M. Weiner. 2001. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 61:4750.
57. Leandro, M. J., J. C. Edwards, G. Cambridge, M. R. Ehrenstein, and D. A. Isenberg. 2002. An open study of B lymphocytes depletion in systemic lupus erythematosus Arthritis Rheum. 46:2673.
58. Dillman, R. O. 1999. Infusion reactions associated with the therapeutic use of monoclonat antibodies in the treatment of malignancy. Cancer Metastasis Rev. 18:465.
59. Bienvenu, J., R. Chvetzoff, G. Salles, C. Balter, H. Tilly, R. Herbrecht, P. Morel, P. Lederlin, P. Solal-Celigny, B. Audhuy, et al. 2001. Tumor necrosis factor-α release is a major biological event associated with Rituximab treatment. Hematol. J. 2:378.
60. Kugathasan, S., M. B. Levy, K. Saeian, S. Vasilopoulos, J. P. Kim, D. Prajapati, J. Emmons, A. Martinez, K. J. Kelly, and D. G. Binion. 2002. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am. J. Gastroenterol. 97:1408.
61. Kreitman, R. J. 1999. Toxin-labeled monoclonal antibodies. Curr. Opin. Immunol. 11:570.
62. Reiter, Y. 2001. Recombinant immunotoxins in targeted cancer cell therapy. Adv. Cancer Res. 81:93.
63. Katre, N. V. 1993. The conjugation of proteins with polyethylene glycol and other polymers: altering properties of proteins to enhance their therapeutic potential. Adv. Drug Dev. Rev. 10:91.